Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODIFY
NCT07456033Phase 3Recruiting
- Sponsor
- GSK
- Start
- Mar 2026
- Primary completion
- Sep 2030
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Depemokimab with Placebo (2 arms). Primary endpoint: Annualized rate of clinically significant exacerbations at 156 weeks. Started Mar 2026; status: recruiting.
02
Drugs
depemokimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07456033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07456033.